These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 11320670

  • 1. Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization of cancer chemotherapeutic regimens.
    Sreerama L, Sládek NE.
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):255-62. PubMed ID: 11320670
    [Abstract] [Full Text] [Related]

  • 2. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens.
    Sládek NE, Kollander R, Sreerama L, Kiang DT.
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):309-21. PubMed ID: 11914911
    [Abstract] [Full Text] [Related]

  • 3. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines.
    Sládek NE.
    Curr Pharm Des; 1999 Aug; 5(8):607-25. PubMed ID: 10469894
    [Abstract] [Full Text] [Related]

  • 4. Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies.
    Sreerama L, Sladek NE.
    Clin Cancer Res; 1997 Nov; 3(11):1901-14. PubMed ID: 9815579
    [Abstract] [Full Text] [Related]

  • 5. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy.
    Khoury T, Ademuyiwa FO, Chandrasekhar R, Jabbour M, Deleo A, Ferrone S, Wang Y, Wang X.
    Mod Pathol; 2012 Mar; 25(3):388-97. PubMed ID: 22080062
    [Abstract] [Full Text] [Related]

  • 6. Multienzyme-mediated stable and transient multidrug resistance and collateral sensitivity induced by xenobiotics.
    Rekha GK, Sladek NE.
    Cancer Chemother Pharmacol; 1997 Mar; 40(3):215-24. PubMed ID: 9219504
    [Abstract] [Full Text] [Related]

  • 7. Over-expression of glutathione S-transferases, DT-diaphorase and an apparently tumour-specific cytosolic class-3 aldehyde dehydrogenase by Warthin tumours and mucoepidermoid carcinomas of the human parotid gland.
    Sreerama L, Sladek NE.
    Arch Oral Biol; 1996 Jun; 41(6):597-605. PubMed ID: 8937651
    [Abstract] [Full Text] [Related]

  • 8. Identification of a class 3 aldehyde dehydrogenase in human saliva and increased levels of this enzyme, glutathione S-transferases, and DT-diaphorase in the saliva of subjects who continually ingest large quantities of coffee or broccoli.
    Sreerama L, Hedge MW, Sladek NE.
    Clin Cancer Res; 1995 Oct; 1(10):1153-63. PubMed ID: 9815907
    [Abstract] [Full Text] [Related]

  • 9. Development of selective inhibitors for human aldehyde dehydrogenase 3A1 (ALDH3A1) for the enhancement of cyclophosphamide cytotoxicity.
    Parajuli B, Georgiadis TM, Fishel ML, Hurley TD.
    Chembiochem; 2014 Mar 21; 15(5):701-12. PubMed ID: 24677340
    [Abstract] [Full Text] [Related]

  • 10. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD.
    Pharmacogenet Genomics; 2008 Jun 21; 18(6):515-23. PubMed ID: 18496131
    [Abstract] [Full Text] [Related]

  • 11. Three different stable human breast adenocarcinoma sublines that overexpress ALDH3A1 and certain other enzymes, apparently as a consequence of constitutively upregulated gene transcription mediated by transactivated EpREs (electrophile responsive elements) present in the 5'-upstream regions of these genes.
    Sreerama L, Sládek NE.
    Chem Biol Interact; 2001 Jan 30; 130-132(1-3):247-60. PubMed ID: 11306049
    [Abstract] [Full Text] [Related]

  • 12. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L, Waxman DJ, Chen D, Kufe DW.
    Cancer Res; 1996 Mar 15; 56(6):1331-40. PubMed ID: 8640822
    [Abstract] [Full Text] [Related]

  • 13. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance.
    Sreerama L, Sladek NE.
    Cancer Res; 1994 Apr 15; 54(8):2176-85. PubMed ID: 8174125
    [Abstract] [Full Text] [Related]

  • 14. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
    Sloderbach A, Górska A, Sikorska M, Misiura K, Hładoń B.
    Postepy Hig Med Dosw (Online); 2013 Dec 10; 67():1235-53. PubMed ID: 24379264
    [Abstract] [Full Text] [Related]

  • 15. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
    Adv Exp Med Biol; 2007 Dec 10; 608():1-22. PubMed ID: 17993229
    [Abstract] [Full Text] [Related]

  • 16. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK, Yu L, Maurel P, Waxman DJ.
    Cancer Res; 1997 May 15; 57(10):1946-54. PubMed ID: 9157990
    [Abstract] [Full Text] [Related]

  • 17. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
    Tanner B, Hengstler JG, Dietrich B, Henrich M, Steinberg P, Weikel W, Meinert R, Kaina B, Oesch F, Knapstein PG.
    Gynecol Oncol; 1997 Apr 15; 65(1):54-62. PubMed ID: 9103391
    [Abstract] [Full Text] [Related]

  • 18. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
    Chen L, Waxman DJ.
    Cancer Res; 1995 Feb 01; 55(3):581-9. PubMed ID: 7834628
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Machiavelli MR, Romero AO, Pérez JE, Lacava JA, Domínguez ME, Rodríguez R, Barbieri MR, Romero Acuña LA, Romero Acuña JM, Langhi MJ, Amato S, Ortiz EH, Vallejo CT, Leone BA.
    Cancer J Sci Am; 1998 Feb 01; 4(2):125-31. PubMed ID: 9554929
    [Abstract] [Full Text] [Related]

  • 20. Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
    Afsar NA, Ufer M, Haenisch S, Remmler C, Mateen A, Usman A, Ahmed KZ, Ahmad HR, Cascorbi I.
    Eur J Clin Pharmacol; 2012 Apr 01; 68(4):389-95. PubMed ID: 22012257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.